“Dave brings to Med BioGene over twenty years of experience in funding and operating life science companies. We are on track to launch LungExpress Dx(TM) in the second half of 2009 in the United States and Dave will play a critical role in executing upon our commercialization strategy” stated Erinn Broshko, chief executive officer of Med BioGene.
“I am excited to join Med BioGene. I believe that the company has one of the best molecular diagnostic test and IP portfolios in the personalized medicine industry,” stated Matthews. “LungExpress Dx(TM) is poised to significantly improve the standard of care for lung cancer and reduce healthcare costs by identifying those patients who will benefit most from adjuvant chemotherapy, in the early stages when lung cancer is curable. I very much look forward to working with management and the board to move Med BioGene this year from a development stage to revenue generating company.”
